US Patent 9,421,192: Daclatasvir Patent Scope, HCV Claims, Exclusivity and Generic Risk
US Patent 9,421,192 covers daclatasvir dihydrochloride, the active pharmaceutical ingredient marketed as Daklinza for hepatitis C virus treatment. Its claims are narrow at the compound level but broad in treatment sequencing and combination use. Claim 1 protects the specific daclatasvir salt. Claims 2 through 8 protect administering that compound for HCV infection, including use with interferons, ribavirin, polymerase inhibitors, protease inhibitors and other anti-HCV agents.
The patent does not claim a broad class of NS5A inhibitors, all daclatasvir salts, a finished tablet, a manufacturing process, or every possible HCV regimen. Its principal commercial value is protection of the daclatasvir molecule and selected combination-treatment uses.
What drug does US Patent 9,421,192 protect?
The compound in claim 1 is daclatasvir dihydrochloride, also known as BMS-790052. Daclatasvir is a direct-acting antiviral that inhibits the HCV NS5A protein. The approved product is Daklinza, developed by Bristol-Myers Squibb.
| Item |
Analysis |
| Active ingredient |
Daclatasvir |
| Salt claimed |
Dihydrochloride |
| Development code |
BMS-790052 |
| Brand |
Daklinza |
| Viral target |
HCV NS5A |
| Drug class |
Direct-acting antiviral |
| Molecular type |
Small molecule |
| Claim 1 |
Specific daclatasvir dihydrochloride compound |
| Claims 2-8 |
HCV treatment and combination methods |
| Regulatory pathway |
New drug application, not a biologics license application |
FDA approved Daklinza in 2015 in combination with sofosbuvir for certain patients with chronic HCV genotype 1 or 3 infection. The label later reflected additional clinical and treatment information.[2]
What does claim 1 cover?
Claim 1 is a product claim directed to one chemically defined compound: daclatasvir dihydrochloride.
The claim identifies:
- The complete stereochemical configuration of the molecule.
- The biphenyl core.
- Two imidazole rings.
- Two pyrrolidine-containing substituents.
- The methyl carbamate groups.
- The branched methyl-containing amino-acid-derived portions.
- The dihydrochloride salt form.
This is a species claim rather than a broad Markush claim. It does not expressly cover every compound having the same pharmacophore or every HCV NS5A inhibitor.
Why the salt limitation matters
The claim is directed to the dihydrochloride salt. A generic applicant seeking to market daclatasvir in a different salt, polymorph, solvate or co-crystal would need to assess whether the alternative form nevertheless falls within the claim under literal infringement or the doctrine of equivalents.
The wording does not expressly claim:
- Free-base daclatasvir.
- Daclatasvir acetate, sulfate or other salts.
- All hydrates or solvates.
- A specific crystal polymorph.
- Particle size or solid-state characteristics.
- A tablet, capsule or injectable dosage form.
If a separate patent claims a particular polymorph, formulation or manufacturing process, that patent could create additional barriers even if the product is outside claim 1.
How broad are the HCV treatment claims?
Claim 2 covers administering a therapeutically effective amount of daclatasvir dihydrochloride to a patient with HCV infection. The claim does not limit the patient by genotype, fibrosis stage, prior treatment history, cirrhosis status or route of administration.
That creates a broad method-of-treatment perimeter relative to the approved label. The claim language potentially reaches use in:
- Different HCV genotypes.
- Treatment-naive and treatment-experienced patients.
- Patients with or without cirrhosis.
- Various treatment durations.
- Different dosage regimens.
- Combination or monotherapy settings, subject to the claim structure and applicable clinical-use facts.
The phrase "therapeutically effective amount" is functional. It does not specify a numerical dose in the supplied claim text. The scope therefore depends on whether the administered amount is intended to produce a therapeutic HCV effect.
What does claim 3 add?
Claim 3 requires daclatasvir plus one or two additional compounds having anti-HCV activity. The additional agent may be administered:
- Before daclatasvir.
- After daclatasvir.
- Simultaneously with daclatasvir.
The claim covers sequential and concurrent combination treatment. It is not restricted to a fixed-dose combination product.
What does claim 4 add?
Claim 4 requires that at least one additional anti-HCV compound be interferon or ribavirin.
This captures historical HCV treatment combinations, including daclatasvir used with ribavirin or interferon-based regimens. It does not require both interferon and ribavirin.
What does claim 5 add?
Claim 5 narrows the interferon category to:
- Interferon alpha 2B.
- Pegylated interferon alpha.
- Consensus interferon.
- Interferon alpha 2A.
- Lymphoblastoid interferon tau.
This is a closed selection from the broader interferon concept in claim 4.
What does claim 6 add?
Claim 6 covers combinations with a range of immunomodulatory, antiviral and host-targeting agents, including:
- Interleukin 2.
- Interleukin 6.
- Interleukin 12.
- Agents that enhance a type 1 helper T-cell response.
- Interfering RNA.
- Antisense RNA.
- Imiquimod.
- Ribavirin.
- IMPDH inhibitors.
- Amantadine.
- Rimantadine.
The claim is commercially less important than the daclatasvir product claim because several listed agents are obsolete or uncommon in modern HCV treatment. It may still have relevance to historical use, patent enforcement theories and combination research.
What do claims 7 and 8 add?
Claims 7 and 8 cover combination therapy with an agent that inhibits specified HCV or host targets.
Claim 7 identifies:
- HCV metalloprotease.
- HCV serine protease.
- HCV polymerase.
- HCV helicase.
- HCV NS4B.
- HCV entry.
- HCV assembly.
- HCV egress.
- HCV NS5A.
- IMPDH.
Claim 8 narrows the additional agent to an inhibitor of:
- HCV serine protease; or
- HCV polymerase.
These claims can reach combinations involving different direct-acting antiviral classes, including protease inhibitors and polymerase inhibitors. They do not require that the additional compound be marketed, approved, or identified by a particular chemical name in the claim text.
How does the claim hierarchy affect infringement risk?
The claims form a descending hierarchy:
| Claim |
Scope |
Commercial significance |
| 1 |
Daclatasvir dihydrochloride compound |
Primary API protection |
| 2 |
Use of daclatasvir for HCV infection |
Broad treatment-use protection |
| 3 |
Daclatasvir plus one or two anti-HCV agents |
Combination-use protection |
| 4 |
Claim 3 with interferon or ribavirin |
Historical combination coverage |
| 5 |
Claim 4 with specified interferons |
Narrow interferon subset |
| 6 |
Claim 3 with specified immune or antiviral agents |
Alternative combination coverage |
| 7 |
Claim 3 with inhibitors of listed HCV or host targets |
Mechanism-based combination coverage |
| 8 |
Claim 3 with serine-protease or polymerase inhibitor |
Narrower DAA combinations |
A product that contains daclatasvir dihydrochloride may implicate claim 1 without relying on any treatment indication. A product that avoids claim 1 through a different salt may still face method-of-use risk if the marketed use practices claim 2 or a dependent combination claim.
What patents protect daclatasvir beyond US 9,421,192?
Daclatasvir's patent estate is likely to include several categories:
| Patent category |
Typical subject matter |
Relevance |
| Core compound patents |
Daclatasvir and related NS5A compounds |
Highest API risk |
| Salt patents |
Dihydrochloride and other pharmaceutical salts |
Salt-selection risk |
| Polymorph patents |
Crystal forms, hydrates and solvates |
Solid-state protection |
| Formulation patents |
Tablets, excipients and dosage forms |
Product-specific risk |
| Method patents |
HCV treatment and combination therapy |
Label and induced-infringement risk |
| Manufacturing patents |
Intermediates, coupling reactions and purification |
Supply-chain and process risk |
| Combination patents |
Daclatasvir with sofosbuvir or other DAAs |
Regimen-specific risk |
US Patent 9,421,192, based on the supplied claims, is primarily a compound and treatment-method patent. The claims do not establish coverage of a specific tablet formulation or manufacturing route.
A complete freedom-to-operate review must separate patents that claim the API from patents that claim the approved product, dosage form, polymorph, synthesis or labeled indication. A generic applicant may avoid one category while remaining exposed to another.
When does US Patent 9,421,192 lose exclusivity?
The patent was issued on Aug. 23, 2016. Patent expiration depends on the earliest effective nonprovisional filing date, applicable priority claims, patent-term adjustment and any terminal disclaimer. The grant date alone does not establish the expiration date.
For US pharmaceutical patents, the ordinary statutory term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and patent-term extension under 35 U.S.C. §§ 154 and 156.[3]
The relevant exclusivity analysis is:
| Exclusivity type |
Effect |
| Patent term |
Bars infringing manufacture, use, sale or importation |
| FDA new-drug exclusivity |
Separate regulatory exclusivity period |
| Orphan-drug exclusivity |
Applies only if the product received orphan designation and approval |
| Pediatric exclusivity |
Can add six months to certain listed protections |
| Orange Book listing |
Links listed patents to ANDA certification obligations |
| Patent-term extension |
May extend one qualifying patent for regulatory review time |
Daclatasvir was approved in 2015, but approval does not itself determine the expiration of US 9,421,192. The patent's front page, USPTO Patent Center records and FDA Orange Book listing must be reconciled before setting a definitive launch date.
What is the Orange Book status of US 9,421,192?
The supplied claims do not establish whether US 9,421,192 is currently listed in the FDA Orange Book for Daklinza. Orange Book listing is a regulatory-record question, not a conclusion that can be drawn from claim language alone.
If listed against the daclatasvir product, the patent could require an ANDA applicant to submit one of the following certifications:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the patent has expired.
- Paragraph III: the applicant will not market before expiration.
- Paragraph IV: the patent is invalid, unenforceable or will not be infringed.
A Paragraph IV certification can trigger patent litigation if the NDA holder or patent owner files suit within the statutory period. The commercial effect depends on the specific NDA, listed patent, certification date and litigation outcome.[4]
What generic entry risks exist for daclatasvir?
The main generic-entry risks are different for the API, salt, treatment indication and formulation.
API and salt risk
A generic daclatasvir product using the claimed dihydrochloride form faces the clearest literal-infringement risk under claim 1, assuming the patent remains enforceable and unexpired.
A different salt may reduce literal product-claim exposure but does not automatically eliminate:
- Equivalence arguments.
- Method-of-use exposure.
- Separate salt or polymorph patents.
- FDA pharmaceutical-equivalence requirements.
- Manufacturing-process patent exposure.
Method-of-use risk
Claims 2 through 8 may create risk for a product label that instructs use of daclatasvir for HCV infection or use with another anti-HCV agent. A generic applicant may seek a section viii statement and omit patented indications where FDA requirements permit. That strategy depends on the listed patent claims, the approved labeling and whether the remaining label still induces infringement.[5]
Combination-product risk
The combination claims are most relevant to regimens involving:
- Daclatasvir plus ribavirin.
- Daclatasvir plus interferon.
- Daclatasvir plus an HCV protease inhibitor.
- Daclatasvir plus an HCV polymerase inhibitor.
- Daclatasvir plus another NS5A-directed agent.
A label that recommends or describes a patented combination can create exposure even if the generic product is chemically identical to the reference product only in the daclatasvir component.
Does biosimilar law apply to daclatasvir?
No. Daclatasvir is a chemically synthesized small molecule, not a biologic subject to the Biologics Price Competition and Innovation Act biosimilar pathway.
The relevant US entry route is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, or, in some circumstances, a 505(b)(2) application. The applicant must assess pharmaceutical equivalence, bioequivalence, labeling, patent certifications and any applicable regulatory exclusivity.[4]
Biosimilar interchangeability, reference-product exclusivity under the Public Health Service Act and biologic patent dance procedures are not the governing framework for daclatasvir.
Which companies are challenging the daclatasvir patent estate?
The supplied claim text does not identify an ANDA filer, Paragraph IV notice, district-court action, appellate decision or settlement agreement. Patent ownership, FDA listing and litigation history must be verified from USPTO, FDA and PACER records before attributing a challenge to a specific company.
No litigation or settlement conclusion should be inferred solely from the existence of claims 1 through 8.
How strong is the patent estate for daclatasvir?
The strongest feature is claim 1's direct coverage of the named active pharmaceutical ingredient in a defined salt form. A generic product that uses the same daclatasvir dihydrochloride API would face a direct product-claim analysis.
The treatment claims provide secondary protection but are more vulnerable to:
- Prior-art arguments involving HCV combination therapy.
- Written-description and enablement challenges across broad target classes.
- Label carve-outs.
- Non-infringing treatment indications.
- Changes in standard-of-care regimens.
- Questions over whether a physician, patient or manufacturer performs the claimed steps.
The claims do not, on their face, provide strong protection for a new formulation, polymorph or manufacturing process unless separate claims in the patent or related patents do so.
What licensing and commercial exposure matter?
Bristol-Myers Squibb developed daclatasvir and commercialized Daklinza. Daclatasvir was positioned as part of the direct-acting antiviral market, where competition included sofosbuvir, ledipasvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, elbasvir, grazoprevir and velpatasvir.
The principal commercial exposure is the US and international daclatasvir franchise rather than a broad platform-technology royalty stream. Licensing, regional commercialization and generic settlements must be analyzed agreement by agreement. The patent claims alone do not establish royalty obligations, authorized-generic arrangements or launch dates.
Key Takeaways
- US Patent 9,421,192 claims daclatasvir dihydrochloride and HCV treatment methods.
- Claim 1 is the most commercially important claim because it directly targets the API in a specified salt form.
- Claims 2 through 8 cover HCV treatment and combinations with interferon, ribavirin, protease inhibitors, polymerase inhibitors and other antiviral or immunomodulatory agents.
- The patent does not, based on the supplied claims, expressly cover every daclatasvir salt, polymorph, formulation or manufacturing process.
- Daclatasvir is a small molecule, so generic entry proceeds through the ANDA framework rather than biosimilar law.
- Orange Book listing, Paragraph IV challenges, litigation and settlements cannot be established from the claim text alone.
- Definitive expiration analysis requires the patent's priority chain, term adjustment, terminal-disclaimer status and any patent-term extension.
- Generic risk is highest for a product using daclatasvir dihydrochloride and carrying an HCV treatment label that practices the claimed methods.
FAQs
Is US Patent 9,421,192 a daclatasvir patent?
Yes. The claimed compound is daclatasvir dihydrochloride, also known as BMS-790052.
Does the patent cover sofosbuvir?
No. The supplied claims do not claim sofosbuvir as a compound. They may reach certain combinations involving an HCV polymerase inhibitor, depending on how the combination claims are construed.
Does the patent cover all NS5A inhibitors?
No. Claim 1 is directed to the specifically recited daclatasvir compound. Claims 2 through 8 require use of that compound.
Can a generic company avoid the patent by using a different daclatasvir salt?
Possibly, but a different salt would require a separate infringement and validity analysis. Method claims, salt patents, polymorph patents and equivalence theories may remain relevant.
Is a Paragraph IV certification required for every daclatasvir ANDA?
Not necessarily. The required certification depends on the patents listed for the reference product, their status, the ANDA's proposed labeling and whether the applicant can use a section viii statement or another permissible route.
References
-
United States Patent No. 9,421,192. (2016). United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2015). Daklinza (daclatasvir) prescribing information. FDA.
-
United States Code, 35 U.S.C. §§ 154, 156.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
United States Code, 21 U.S.C. § 355; 21 C.F.R. § 314.94.